FiercePharma · 2d
With Novo CEO on the hot seat at Senate hearing, PBMs and insurance concerns get the spotlight
When government officials and politicians scrutinize high U.S. drug prices, the role of insurers and pharmacy benefit managers (PBMs) often commands at least some of the attention. | At the Senate committee hearing on Novo Nordisk's prices for Ozempic and Wegovy,
NBC DFW · 3d
Maker of Ozempic and Wegovy faces grilling over high cost of weight loss drugs
The chief executive of the drugmaker Novo Nordisk, Lars Fruergaard Jørgensen, is scheduled to face tough questions Tuesday on Capitol Hill about the high costs of the company’s widely popular weight-loss drugs. Jørgensen will appear before the Senate ...
WRAL · 2d
Ozempic, Wegovy maker Novo Nordisk questioned over high cost of weight-loss drugs
U.S. senators questioned Novo Nordisk CEO Lars Fruergaard Jørgensen about the high costs of the company's GLP-1 drugs, which include popular weight-loss drugs Wegovy and Ozempic. It comes after North Carolina cut the weight-loss drugs from its state health plan.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results